Table 1. Study Design
Randomized controlled double-blind study on the safety and effectiveness of thalidomide in the treatment of refractory Crohn’s disease and ulcerative colitis

Phase I
INDUCTION OF REMISSION
RCT Double-Blind, 8 weeks
Outcome: Clinical Response 75% or Remission

Phase II
MAINTAINING OF REMISSION
Open-label, 52 weeks
Outcome: Maintaining of Remission